Eric A Sribnick, Angelo M Del Re, Swapan K Ray, John J Woodward, Naren L Banik
Index: Brain Res. 1276 , 159-70, (2009)
Full Text: HTML
Estrogen-mediated neuroprotection is observed in neurodegenerative disease and neurotrauma models; however, determining a mechanism for these effects has been difficult. We propose that estrogen may limit cell death in the nervous system tissue by inhibiting increases in intracellular free Ca(2+). Here, we present data using VSC 4.1 cell line, a ventral spinal motoneuron and neuroblastoma hybrid cell line. Treatment with 1 mM glutamate for 24 h induced apoptosis. When cells were pre-treated with 100 nM 17beta-estradiol (estrogen) for 1 h and then co-treated with glutamate, apoptotic death was significantly attenuated. Estrogen also prevented glutamate-mediated changes in resting membrane potential and membrane capacitance. Treatment with either 17 alpha-estradiol or cell impermeable estrogen did not mimic the findings seen with estrogen. Glutamate treatment significantly increased both intracellular free Ca(2+) and the activities of downstream proteases such as calpain and caspase-3. Estrogen attenuated both the increases in intracellular free Ca(2+) and protease activities. In order to determine the pathway responsible for estrogen-mediated inhibition of these increases in intracellular free Ca(2+), cells were treated with several Ca(2+) entry inhibitors, but only the L-type Ca(2+) channel blocker nifedipine demonstrated cytoprotective effects comparable to estrogen. To expand these findings, cells were treated with the L-type Ca(2+) channel agonist FPL 64176, which increased both cell death and intracellular free Ca(2+), and estrogen inhibited both effects. From these observations, we conclude that estrogen limits glutamate-induced cell death in VSC 4.1 cells through effects on L-type Ca(2+) channels, inhibiting Ca(2+) influx as well as activation of the pro-apoptotic proteases calpain and caspase-3.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
FPL64176
CAS:120934-96-5 |
C22H21NO3 |
Metformin as adjunct antituberculosis therapy.
2014-11-19 [Sci. Transl. Med. 6(263) , 263ra159, (2014)] |
A pharmacological model for calcium overload-induced tachyca...
2007-12-08 [Eur. J. Pharmacol. 576(1-3) , 122-31, (2007)] |
Acute atrial arrhythmogenesis in murine hearts following enh...
2010-02-01 [Acta Physiol. (Oxf.) 198(2) , 143-58, (2010)] |
Perspective on the role of P2X-purinoceptor activation in hu...
2012-05-01 [Exp. Physiol. 97(5) , 583-602, (2012)] |
An L-type calcium channel agonist, bay K8644, extends the wi...
2013-02-01 [Mol. Neurobiol. 47(1) , 280-9, (2013)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved